📰 Research Report Initial Coverage News
Research Report Initial Coverage News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Research Report Initial Coverage. Real-time updates on events, politics, business and more.
May 11, 2023
Original-Research: Mexedia S.p.A. - von GBC AG Einstufung von GBC AG zu Mexedia S.p.A. Unternehmen: Mexedia S.p.A. ISIN: IT0005450819 Anlass der Studie: Research Report (Initial Coverage) Empfehlung:
May 11, 2023
Research Report MEXEDIA S.p.A. - Società Benefit From Telecom to Tech - Driving Innovation with Customer... | May 11, 2023
May 11, 2023
Research Report MEXEDIA S.p.A. - Società Benefit From Telecom to Tech - Driving Innovation with Customer... | May 11, 2023
May 11, 2023
Research Report MEXEDIA S.p.A. - Società Benefit From Telecom to Tech - Driving Innovation with Customer... | May 11, 2023
April 5, 2023
Original-Research: First Tin Plc - von GBC AG Einstufung von GBC AG zu First Tin Plc Unternehmen: First Tin Plc ISIN: GB00BNR45554 Anlass der Studie: Research Report (Initial Coverage) Empfehlung:
November 7, 2022
Original-Research: publity AG - von GBC AG Einstufung von GBC AG zu publity AG Unternehmen: publity AG ISIN: DE0006972508 Anlass der Studie: Research Report (Initial Coverage) Empfehlung: BUY
July 13, 2022
Original-Research: Advanced Blockchain AG - von GBC AG Einstufung von GBC AG zu Advanced Blockchain AG Unternehmen: Advanced Blockchain AG ISIN: DE000A0M93V6 Anlass der Studie: Research Report
June 29, 2022
Original-Research: EAMD European AeroMarine Drones AG - von GBC AG Einstufung von GBC AG zu EAMD European AeroMarine Drones AG Unternehmen: EAMD European AeroMarine Drones AG ISIN: DE0006611957
February 10, 2022
^ Original-Research: Defence Therapeutics Inc. - von GBC AG Einstufung von GBC AG zu Defence Therapeutics Inc. Unternehmen: Defence Therapeutics Inc. ISIN: CA24463V1013 Anlass der Studie: Research Report (Initial Coverage) Empfehlung: BUY Kursziel: 11,02 CAD (7,06 EUR) Kursziel auf Sicht von: 31...
February 10, 2022
Original-Research: Defence Therapeutics Inc. - von GBC AG Einstufung von GBC AG zu Defence Therapeutics Inc. Unternehmen: Defence Therapeutics Inc. ISIN: CA24463V1013 Anlass der Studie: Research